Evidence map›Paper›PMID 35185770›Full record

ArticleFrontiers in neurology2022

T2/FLAIR Abnormity Could be the Sign of Glioblastoma Dissemination.

Mingxiao Li, Wei Huang, Hongyan Chen, Haihui Jiang, Chuanwei Yang, Shaoping Shen, Yong Cui, Gehong Dong, Xiaohui Ren, Song Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mingxiao LiDepartment of Neurosurgical Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Wei HuangDepartment of Neurosurgical Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Hongyan ChenDepartment of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Haihui JiangDepartment of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, China.
Chuanwei YangDepartment of Neurosurgical Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Shaoping ShenDepartment of Neurosurgical Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yong CuiDepartment of Neurosurgical Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Gehong DongDepartment of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xiaohui RenDepartment of Neurosurgical Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Song LinDepartment of Neurosurgical Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNewly emerged or constantly enlarged contrast-enhancing (CE) lesions were the necessary signs for the diagnosis of glioblastoma (GBM) progression. This study aimed to investigate whether the T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) abnormal transformation could predict and assess progression for GBMs, especially for tumor dissemination.

methodsA consecutive cohort of 246 GBM patients with regular follow-up and sufficient radiological data was included in this study. The series of T2/FLAIR and T1CE images were retrospectively reviewed. The patients were separated into T2/FLAIR and T1CE discordant and accordant subgroups based on the initial progression images.

resultsA total of 170 qualified patients were finally analyzed. The incidence of discordant T2/FLAIR and T1CE images was 25.9% (44/170). The median time-span of T2/FLAIR indicated tumor progression was 119.5 days (ranging from 57 days-unreached) prior to T1CE. Nearly half of patients (20/44, 45.5%) in the discordant subgroup suffered from tumor dissemination, substantially higher than accordant patients (23/126, 20.6%,

conclusionsT2/FLAIR abnormity could be the sign of GBM progression, especially for newly emerged lesions disseminating from the primary cavity. Physicians should cast more attention on the dynamic change of T2/FLAIR images, which might be of great significance for progression assessment and subsequent clinical decision-making.

Indexed as

disseminationglioblastoma (GBM)gross total removal of tumor (GTR)isocitrate dehydrogenase (IDH)progressionRANOsupratotal maximal resection (SMR)T2/FLAIR

Identifiers

PMID35185770
PMCPMC8849106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.